Marine sponge metabolites for the control of inflammatory diseases

Current Opinion in Investigational Drugs

Volumn 7, Issue 11, 2006, Pages 974-979

  Alcaraz, Maria José ^a   Payá, Miguel ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Anti inflammatory drug; Arthritis; Intestinal inflammation; Marine metabolite; Nuclear factor B; Phospholipase A2; Sponge

Indexed keywords

2 POLYPRENYL 1,4 HYDROQUINONE DERIVATIVE; ANTIINFLAMMATORY AGENT; AVAROL; BOLINAQUINONE; CACOSPONGIONOLIDE B; CAVERNOLIDE; CYCLOOXYGENASE 2; DEXAMETHASONE; DYSIDENONE A; DYSIDENONE B; DYSIDINE; DYSIDOTRONIC ACID; EPITAONDIOL; GLUCOCORTICOID; INDOMETACIN; IRCININ; LUFFARIELLOLIDE; MANOALIDE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NATURAL PRODUCT; PETROSASPONGIOLIDE M; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHOLIPASE C; SCALARADIAL; SESQUITERPENE AMINOQUINONE DERIVATIVE; SESQUITERPENE CYCLOPENTANONE DERIVATIVE; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARIABILIN;

ANTIINFLAMMATORY ACTIVITY; AQUACULTURE; CLINICAL TRIAL; COLITIS; CYTOKINE PRODUCTION; DERMATITIS; DISEASE CONTROL; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNOVIAL FLUID LEVEL; DRUG TARGETING; ENTERITIS; ENZYME ANALYSIS; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; INFLAMMATORY DISEASE; INVERTEBRATE; METABOLITE; NONHUMAN; OSTEOARTHRITIS; PROTEIN TARGETING; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLAMMATION; MOLECULAR STRUCTURE; PORIFERA; TECHNOLOGY, PHARMACEUTICAL; TREATMENT OUTCOME;

EID: 33751063288     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Proksch P, Edrada RA, Ebel R: Drugs from the seas - current status and microbiological implications. Appl Microbiol Biotechnol (2002) 59(2-3):125-134.
2. De Silva ED, Scheuer PJ: Manoalide, an antibiotic sesterterpenoid from the marine sponge Luffariella variabilis (polejaeff). Tetrahedron Lett (1980) 21(17):1611-1614.
3. Allergan Inc: Drug development pipeline. Company Communication (1999): June 29.
4. 2 enzymes: Regulation and inhibition. Trends Pharmacol Sci (1993) 14(3):92-98.
5. 2 superfamily of signal transduction enzymes. Trends Biochem Sci (1997) 22(1):1-2.
6. 2-mediated release of arachidonic acid is critical for proliferation of vascular smooth muscle cells. J Biol Chem (1997) 272(48):30504-30511.
7. 2. Eur J Pharmacol (1997) 326(2-3):237-250.
8. 2. Annu Rev Pharmacol Toxicol (1999) 39:175-189.
9. 2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes. J Immunol (2000) 165(5):2790-2797.
10. 2. Biochem Pharmacol (1986) 35(3):449-453.
11. 2 inhibition by manoalide. A novel type of phospholipase inhibitor. J Biol Chem (1985) 260(12):7234-7240.
12. 2 by the marine natural product, manoalide. Biochem Pharmacol (1990) 39(10):1557-1564.
13. 2. Biochem Pharmacol (1988) 37(19):3639-3646.
14. 2 inactivation. Mol Pharmacol (1989) 36(5):782-788.
15. Soriente A, De Rosa MMC, Scettri A, Sodano G, Terencio MC, Paya M, Alcaraz MJ: Manoalide. Curr Med Chem (1999) 6(5):415-431.
16. 2. Skin Pharmacol (1995) 8(6):300-308.
17. De Rosa S, Crispino A, De Giulio A, Iodice C, Pronzato R, Zavodnik N: Cacospongionolide B, a new sesterterpene from the sponge Fasciospongia cavernosa. J Nat Prod (1995) 58(11):1776-1780.
18. 2 inhibitors from the new caledonian marine sponge Petrosaspongia nigra. J Nat Prod (1998) 61(5):571-575.
19. De Rosa M, Giordano S, Scettri A, Sodano G, Soriente A, Pastor PG, Alcaraz MJ, Payá M: Synthesis and comparison of the antiinflammatory activity of manoalide and cacospongionolide B analogues. J Med Chem (1998) 41(17):3232-3238.
20. 2. Br J Pharmacol (1999) 126(1):301-311.
21. 2 inhibitor, on acute and chronic inflammation. J Pharmacol Exp Ther (1999) 289(1):166-172.
22. 2 activities and some inflammatory responses by the marine product ircinin. Naunyn Schmiedeberg's Arch Pharmacol (1996) 354(5):677-683.
23. Ferrándiz ML, Sanz MJ, Bustos G, Payá M, Alcaraz MJ, De Rosa S: Avarol and avarone, two new anti-inflammatory agents of marine origin. Eur J Pharmacol (1994) 253(1-2):75-82.
24. 2 activity and some inflammatory responses. Eur J Pharmacol (1995) 285(3):281-288.
25. Terencio MC, Ferrándiz ML, Posadas I, Roig E, De Rosa S, De Giulio A, Payá M, Alcaraz MJ: Suppression of leukotriene B4 and tumour necrosis factor α release in acute inflammatory responses by novel prenylated hydroquinone derivatives. Naunyn Schmiedeberg's Arch Pharmacol (1998) 357(5):565-572.
26. Gil B, Ferrándiz ML, Sanz MJ, Terencio MC, Ubeda A, Rovirosa J, San-Martin A, Alcaraz MJ, Payá M: Inhibition of inflammatory responses by epitaondiol and other marine natural products. Life Sci (1995) 57(2):PL25-PL30.
27. 2 sharing unusual chemical features. Life Sci (2000) 67(24):3007-3014.
28. Posadas I, Terencio MC, Giannini C, D'Auria MV, Payá M: Dysidotronic acid, a new sesquiterpenoid, inhibits cytokine production and the expression of nitric oxide synthase. Eur J Pharmacol (2001) 415(2-3):285-292.
29. 2 and other leukocyte functions. J Nat Prod (2001) 64(5):612-615.
30. 2 inhibitor, manoalide, on cartilage degradation, stromelysin expression, and synovial fluid cell count induced by intra-articular injection of human recombinant interleukin-1 α in the rabbit. Arthritis Rheum (1996) 38(8):1292-1299.
31. 2 with anti-inflammatory activity. J Pharmacol Exp Ther (1997) 282(1):123-131.
32. California sea grant strategic plan 2001-2005. New marine products. SeaGrant California, La Jolla, CA, USA (2003). http://www-csgc.ucsd.edu/ NEWS/NEWS_PDFs/MarProd.pdf
33. 2 generation and proliferation in the HaCaT cell line. J Nat Prod (2004) 67(9):1459-1463.
34. Lucas R, Giannini C, D'Auria MV, Paya M: Modulatory effect of bolinaquinone, a marine sesquiterpenoid, on acute and chronic inflammatory processes. J Pharmacol Exp Ther (2003) 304(3):1172-1180.
35. Feldmann M, Maini RN: The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) (1999) 38(Suppl 2):3-7.
36. Goldring MB: Osteoarthritis and cartilage: The role of cytokines. Curr Rheumatol Rep (2000) 2(6):459-465.
37. Rogler G, Andus T: Cytokines in inflammatory bowel disease. World J Surg (1998) 22(4):382-389.
38. 2 activating protein and idiopathic inflammatory bowel disease. Gut (1996) 39(5):698-704.
39. Busserolles J, Paya M, D'Auria MV, Gomez-Paloma L, Alcaraz MJ: Protection against 2,4,6-trinitrobenzenesulphonic acid-induced colonic inflammation in mice by the marine products bolinaquinone and petrosaspongiolide M. Biochem Pharmacol (2005) 69(10):1433-1440.
40. De Vries GW, Amdahl L, Mobasser A, Wenzel M, Wheeler LA: Preferential inhibition of 5-lipoxygenase activity by manoalide. Biochem Pharmacol (1988) 37(15):2899-2905.
41. Bennett CF, Mong S, Wu H-LW, Clark MA, Wheeler L, Crooke ST: Inhibition of phosphoinositide-specific phospholipase C by manoalide. Mol Pharmacol (1987) 32(5):587-593.
42. Posadas I, De Rosa S, Terencio MC, Paya M, Alcaraz MJ: Cacospongionolide B suppresses the expression of inflammatory enzymes and tumour necrosis factor-α by inhibiting nuclear factor-κB activation. Br J Pharmacol (2003) 138(8):1571-1579.
43. Posadas I, Terencio MC, Randazzo A, Gomez-Paloma L, Paya M, Alcaraz MJ: Inhibition of the NF-κB signaling pathway mediates the anti-inflammatory effects of petrosaspongiolide M. Biochem Pharmacol (2003) 65(5):887-895.
44. Breton JJ, Chabot-Fletcher MC: The natural product hymenialdisine inhibits interleukin-8 production in U937 cells by inhibition of nuclear factor-κB. J Pharmacol Exp Ther (1997) 282(1):459-466.
45. 2 formation by the marine natural product hymenialdisine. J Pharmacol Exp Ther (1997) 283(2):955-961.
46. De Rosa S, De Caro S, Iodice C, Tommonaro G, Stefanov K, Popov S: Development in primary cell culture of demosponges. J Biotechnol (2003) 100(2):119-125.
47. Muller WE, Grebenjuk VA, Le Pennec G, Schroder H, Brummer F, Hentschel U, Muller IM, Breter H: Sustainable production of bioactive compounds by sponges - cell culture and gene cluster approach: A review. Mar Biotechnol (NY) (2004) 6(2):105-117.
48. Breter HJ, Grebenjuk VA, Skorokhod A, Muller WE: Approaches for a sustainable use of the bioactive potential in sponges: Analysis of gene clusters, differential display of mRNA and DNA chips. Prog Mol Subcell Biol (2003) 37:199-230.
49. 2 inhibitor from the sponge Dysidea sp. Tetrahedron Lett (2000) 41(17):3257-3260.
50. Mayer AM, Spitzer JA: Modulation of superoxide anion generation by manoalide, arachidonic acid and staurosporine in liver infiltrated neutrophils in a rat model of endotoxemia. J Pharmacol Exp Ther (1993) 267(1):400-409.
51. Sharma V, Tape JJ: Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorg Med Chem Lett (2004) 14(16):4319-4321.